Back to Results
First PageMeta Content
Membrane technology / Kidney diseases / Renal dialysis / Detoxification / Dialysis / Erythropoietin / Chronic kidney disease / Peginesatide / Medicine / Nephrology / Anatomy


Peginesatide Affymax, Inc. Briefing Document ODAC Meeting 07 Dec 2011
Add to Reading List

Open Document

File Size: 999,88 KB

Share Result on Facebook

Company

BP / Relevant Treatment Discontinuation Information / Peginesatide Group / Target / excretion AE / EPO / Affymax Inc. / Redaction Peginesatide Affymax Inc. / Peginesatide Affymax Inc. / /

Country

United States / /

Currency

pence / /

Event

FDA Phase / /

IndustryTerm

treatment of anemia due to chronic kidney disease / /

MedicalCondition

ERC event review committee ESA erythropoiesis stimulating agent ESRD / PVD peripheral vascular disease QW / congestive heart failure CI / chronic kidney disease / gene HF heart failure HR / MI myocardial infarction NAb / anemia CKD / CAD coronary artery disease CHF / anemia / Pure Red Cell Aplasia / /

MedicalTreatment

chemotherapy / dialysis / /

Organization

New Zealand PD / Temporal Association / Central Intelligence Agency / African Union / FDA Food and Drug Administration / Administration for Mean Change / European Union / NHS / /

Person

Adverse Cardiovascular / /

Position

Hb / Confirmed Hb / EXECUTIVE / Major / General / Explanation Hb / /

Product

polyethylene glycol / Death (Non-Dialysis Population) / Harmonisation Inj injection / Peginesatide / /

PublishedMedium

Baseline / /

RadioStation

Core / /

Technology

chemotherapy / ESA / dialysis / CAD / /

SocialTag